IDEAYA Biosciences, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
IDEAYA Biosciences, Inc. (IDYA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther · last filed 2026-02-17
- IDEAYA Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2025 was 0.00%.
- IDEAYA Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2024 was 0.00%.
- IDEAYA Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2023 was -0.10%.
- IDEAYA Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2022 was -0.10%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | 0.00% 10-K · filed 2026-02-17 | |
| 2024-12-31 | 0.00% 10-K · filed 2026-02-17 | |
| 2023-12-31 | -0.10% 10-K · filed 2026-02-17 | |
| 2022-12-31 | -0.10% 10-K · filed 2025-02-18 | |
| 2021-12-31 | -0.10% 10-K · filed 2024-02-20 | -0.30% 10-K · filed 2022-03-18 |
| 2020-12-31 | 0.00% 10-K · filed 2023-03-07 | -0.30% 10-K · filed 2021-03-23 |
| 2019-12-31 | -0.40% 10-K · filed 2022-03-18 | |
| 2018-12-31 | -1.30% 10-K · filed 2021-03-23 | |
| 2017-12-31 | -2.10% 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |